Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Empower offers a version of Eli Lillys products in an oral pill form and an injectable mixed with B3 vitamins, neither of which Lilly offers
Clinical and real-world evidence have demonstrated the potential of GLP-1RAs to reduce the risk of all-cause dementia and dementia due to AD in people with T2D [32, 34,35,36], and liraglutide has been shown to reduce neurodegeneration and the speed of decline in cognitive function in people with AD [29, 30]
Nancy G
Exenatide, the first GLP-1RA approved in 2005, demonstrated clinical efficacy but its low homology with human GLP-1 and gastrointestinal side effects restricted widespread use (Muttenthaler et al., 2021)
10.1093/ajcn/nqy041 125
US$ 25.77
US$ 23.21
US$ 28.77
US$ 22.64
US$ 20.21
